Oddway International Is Pleased To Inform Addition Of Efamat Tablets Into Their Product Catalogue

“Efavirenz 600 mg Tablets By Mylan Pharmaceuticals For The Treatment Of HIV”

Press Release (ePRNews.com) - New Delhi, India - Aug 23, 2017 - Oddway International, India’s leading pharmaceutical company, takes great pleasure in introducing yet another effective medication; Efamat manufactured by Mylan Pharmaceuticals contains Efavirenz in its comprehensive product list.

Efavirenz is a nonnucleoside reverse transcriptase inhibitor (NNRTI). It works by blocking the growth of HIV. Efamat 600 mg is used for treating HIV infection. It must be used in combination with other medicines. If Efavirenz is taken alone to treat HIV, it may stop working.

Oddway International provides over thirty categories of product catalogs with hundreds of quality products offered in each category at a reasonable price. They pride themselves on “quality control” and “quality assurance” in order to offer their local and global customers a better health and well-being through the use of their quality medication.

About Oddway International

Oddway International is the fastest growing pharmaceutical exporter operating in India. Their mission is to improve access to quality therapies at affordable prices and to bring high quality healthcare to everyone in need of it. Their portfolio includes medicines, treatments and cures that challenge the most feared socially significant diseases of today’s time. They strive to set the standard for quality, safety and value in the delivering of health care products. For more than 7 years, Oddway has worked to make a difference for all who rely on them.

For more information visit our website http://www.oddwayinternational.com

Source : Pharmaceutical Wholesale Supplier & Exporter In India

You may also like this  

CATEGORIES : Healthcare Medical
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login